Introducing the New Standard in Stroke Surgery

EndoUVtech aims to revolutionize surgical stroke protocols by dramatically improving patient recovery outcomes and reducing post-stroke disabilities. Our mission is to give stroke patients a better chance at full recovery, significantly lowering global healthcare costs associated with post-stroke care.

Current stroke protocols, such as stent retrievers and aspiration devices, remove the primary clot but often leave smaller downstream clots that can lead to severe disabilities. EndoUVtech’s UV laser technology, delivered through a proprietary balloon catheter, not only safely removes the primary clot but also dissolves smaller downstream clots. This dual approach reduces the risk of arterial damage and vastly improves recovery potential for patients.

With 12 million stroke cases globally each year and over $800 billion spent on post-stroke care, the market for advanced stroke treatment is vast. Our Globally patented technology and method along with the licensing model positions EndoUVtech to capture a significant share of this market, representing a multi-billion dollar opportunity.

Unlike pharmaceuticals, which can take 8-10 years for FDA approval, EndoUVtech’s device, as a fully developed medical device, can gain FDA clearance within 36 months. This expedited pathway allows us to bring our life-saving technology to market much quicker. 

Yes, our UV laser technology has undergone successful animal testing at the University of Pennsylvania and human studies in Italy. These trials have demonstrated the efficacy of our approach, positioning us for a streamlined FDA approval process.

EndoUVtech holds four patents on our unique UV laser technology and fiber optic balloon catheter, with three patents issued and two registered internationally. This IP provides us with strong competitive protection as the only company offering this innovative stroke treatment.

By reducing the severe disabilities commonly associated with stroke recovery, EndoUVtech’s technology has the potential to cut global post-stroke care costs in half, an estimated reduction of $350 billion annually. Improved recovery outcomes mean fewer long-term care needs, benefiting both patients and healthcare systems.

EndoUVtech’s leadership includes Chip Van Vurst, a biotech entrepreneur who founded a now publicly traded company generating hundreds of millions annually, and Dr. Brant Watson, a renowned neuroscientist and Professor Emeritus. Together, they lead a skilled team with a proven track record of bringing transformative medical technologies to market.

We are delighted to connect with interested investors. Please reach out through our Contact page to schedule a conversation with a member of our leadership team.